Last reviewed · How we verify

ENOXA® — Competitive Intelligence Brief

ENOXA® (ENOXA®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

marketed RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ENOXA® (ENOXA®) — Les Laboratoires des Médicaments Stériles. Enoxa is a small molecule drug, but its exact mechanism of action is unknown.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ENOXA® TARGET ENOXA® Les Laboratoires des Médicaments Stériles marketed RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ENOXA® — Competitive Intelligence Brief. https://druglandscape.com/ci/enoxa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: